Javier Soria
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Javier Soria has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Almudena Del-Hierro-Zarzuelo
Hospital la Paz, Pº de la Castellana, 261, E-28046 Madrid, Spain
2 shared publicationsArantxa Acera
Bioftalmik Applied Research, Bizkaia Science and Technology Park, Building 612, E-48160 Derio, Bizkaia, Spain
2 shared publications- Iker García
Neuromuscular Disorders, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain
2 shared publications Nerea González
Bioftalmik Applied Research, Bizkaia Science and Technology Park, Building 612, E-48160 Derio, Bizkaia, Spain
2 shared publicationsA. Acera
1 shared publicationA. Baumelou
Department of Nephrology, La Pitié Hospital, Paris, France
1 shared publication
Latest Publications
- 1 February 2018
- Published by Elsevier in Experimental Eye Research
- Vol. 167, 31-43
The analysis of human conjunctival epithelium proteome in ocular surface diseases using impression cytology and 2D-DIGE
- 1 February 2018
- Published by Elsevier in Experimental Eye Research
- Vol. 167, 31-43
The analysis of human conjunctival epithelium proteome in ocular surface diseases using impression cytology and 2D-DIGE
- 1 January 2013
- Published by Elsevier in Journal of Proteomics
- Vol. 78, 94-112
Tear proteome and protein network analyses reveal a novel pentamarker panel for tear film characterization in dry eye and meibomian gland dysfunction
- 1 January 2013
- Published by Elsevier in Journal of Proteomics
- Vol. 78, 94-112
Tear proteome and protein network analyses reveal a novel pentamarker panel for tear film characterization in dry eye and meibomian gland dysfunction
- 1 May 2012
- Published by Elsevier in Ophthalmology
- Vol. 119 (5) , 923-929
Comparative Study of Limbal Stem Cell Deficiency Diagnosis Methods: Detection of MUC5AC mRNA and Goblet Cells in Corneal Epithelium
- 1 May 2012
- Published by Elsevier in Ophthalmology
- Vol. 119 (5) , 923-929
Comparative Study of Limbal Stem Cell Deficiency Diagnosis Methods: Detection of MUC5AC mRNA and Goblet Cells in Corneal Epithelium
- 28 February 2006
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1760 (2) , 172-181
The nitrate/nitrite ABC transporter of Phormidium laminosum: Phosphorylation state of NrtA is not involved in its substrate binding activity
- 28 February 2006
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1760 (2) , 172-181
The nitrate/nitrite ABC transporter of Phormidium laminosum: Phosphorylation state of NrtA is not involved in its substrate binding activity
- 1 July 2001
- Published by Wiley in Artificial Organs
- Vol. 25 (7) , 591-595
Dose Effect Relationship of Reviparin in Chronic Hemodialysis: A Crossover Study Versus Nadroparin
Low molecular weight heparins (LMWHs) are used for prevention of clotting in the dialysis circuit. The aim of this trial was to define the optimal dose of a new LMWH and to test the efficiency of a single dose at the start of the session. Fifteen patients were treated according to a double blind and crossover design during 4 blocks of 5 consecutive reviparin doses assigned randomly as 50, 60, 70, 85, and 100 IU anti‐Xa/kg. Assessment was carried out on screening of fibrin rings or clots in the arterial and venous air traps and on visual detection of fiber in the dialyzer after rinsing. These clinical results were compared to plasmatic anti‐Xa activity and thrombin‐antithrombin (TAT) complex generation. A standard dose of 70 IU anti‐Xa/kg of nadroparin was used as the control. After a bolus of 50 to 100 IU anti‐Xa/kg, the occurrence of fibrin rings and clots in the air traps was dependent on three factors: dose of LMWH, time of the session, and patient status. A bolus of 85 IU anti‐Xa/kg of reviparin was effective and safe for sessions of 4 h. For this dose, plasmatic anti‐Xa activity was 0.96 ± 0.28 IU/ml at Hour 2 and 0.82 ± 0.22 IU/ml at Hour 4. TAT complexes are good markers of the activation of the coagulation. They did not increase during a 4 h session after a reviparin bolus of 100 IU/kg. For the same LMWH dose, the trial shows a great variability of the clinical effect and anti‐Xa activities from one patient to another. A single dose of 85 IU anti‐Xa/kg of reviparin can be used at the start of the dialysis session as a loading dose. We advise adapting the dose during the subsequent sessions according to the appearance of the blood circuit. The benefit of monitoring anti‐Xa activity and TAT complexes could be tested in a further trial.
- 1 July 2001
- Published by Wiley in Artificial Organs
- Vol. 25 (7) , 591-595
Dose Effect Relationship of Reviparin in Chronic Hemodialysis: A Crossover Study Versus Nadroparin
Low molecular weight heparins (LMWHs) are used for prevention of clotting in the dialysis circuit. The aim of this trial was to define the optimal dose of a new LMWH and to test the efficiency of a single dose at the start of the session. Fifteen patients were treated according to a double blind and crossover design during 4 blocks of 5 consecutive reviparin doses assigned randomly as 50, 60, 70, 85, and 100 IU anti‐Xa/kg. Assessment was carried out on screening of fibrin rings or clots in the arterial and venous air traps and on visual detection of fiber in the dialyzer after rinsing. These clinical results were compared to plasmatic anti‐Xa activity and thrombin‐antithrombin (TAT) complex generation. A standard dose of 70 IU anti‐Xa/kg of nadroparin was used as the control. After a bolus of 50 to 100 IU anti‐Xa/kg, the occurrence of fibrin rings and clots in the air traps was dependent on three factors: dose of LMWH, time of the session, and patient status. A bolus of 85 IU anti‐Xa/kg of reviparin was effective and safe for sessions of 4 h. For this dose, plasmatic anti‐Xa activity was 0.96 ± 0.28 IU/ml at Hour 2 and 0.82 ± 0.22 IU/ml at Hour 4. TAT complexes are good markers of the activation of the coagulation. They did not increase during a 4 h session after a reviparin bolus of 100 IU/kg. For the same LMWH dose, the trial shows a great variability of the clinical effect and anti‐Xa activities from one patient to another. A single dose of 85 IU anti‐Xa/kg of reviparin can be used at the start of the dialysis session as a loading dose. We advise adapting the dose during the subsequent sessions according to the appearance of the blood circuit. The benefit of monitoring anti‐Xa activity and TAT complexes could be tested in a further trial.